Roche: Giredestrant Plus Everolimus Cut Risk Of Disease Progression Or Death By 44%—62% In Phase III Advanced Breast Cancer Study

Median Progression-Free Survival Was 8.8 Months In Overall Study Population - Overall Survival Data Showed Positive Trend In Overall And ESR1-Mutated Groups - Adverse Events Manageable, With No Unexpected Safety Findings - FDA Review Deadlines Set For 30 November And 18 December 2026